Sulofenur is an orally active diarylsulfonylurea derivative patented by American pharmaceutical company Eli Lilly and Co. as an antitumor agent. In preclinical studies, Sulofenur exhibits significant activity against advanced colon adenocarcinoma xenografts intrinsically resistant to virtually all standard chemotherapeutic agents and also had very significant activity against several pediatric tumors grown as xenografts. Clinically, Sulofenur was disappointing, and although some responses were reported in phase I trials this was not confirmed for ovarian cancer in the phase II setting. Toxicity in man was due mainly to methemoglobinemia and anemia, which limited the concentrations of drug that could be achieved to levels well below those shown to elicit a therapeutic response in the xenograft models.

Thyropropic Acid (also known as Triopron) is a hydrocinnamic acid derivative and naturally occurring thyroid analog with antigoitrogenic and anticholesteremic activity. Thyropropic Acid acts as potent antagonist of thyroid hormone receptors and may be useful in the therapy of resistance to thyroid hormone and corticosteroid-induced skin atrophy. In preclinical models, Thyropropic Acid reduced serum cholesterol 27% and liver incorporation of acetate into cholesterol 37% but did not affect liver cholesterol levels.

Iodocetylic Acid I-123 is a radiolabeled derivative of cetylic acid. Iodocetylic Acid I-123 was studied as for in vivo diagnosis of the myocardium.

Hyodeoxycholic acid, also known as HDCA, is a secondary bile acid. Natural 6alpha-hydroxylated bile acids are receptor-specific activators of nuclear liver X receptor alpha (LXRalpha), a nuclear receptor regulating the expression of the cholesterol 7alpha-hydroxylase gene. AHRO-001 (Hyodeoxycholic acid) is in phase I clinical trials for the treatment of atherosclerosis. Through a complex signaling processes utilizing LXR receptors, the compound is designed to increase the efficiency of cholesterol efflux using the HDL cells, which act on all cholesterol in the arterial circulation as well as in the lipid core of plaque deposits in the artery walls. Use of AHRO-001 has shown no adverse effects on morbidity, mortality or toxicity and has been well tolerated at high doses.

Tibric Acid is a sulfamoylbenzoic acid derivative patented by American multinational pharmaceutical corporation Pfizer Inc. as a hypolipidemic agent. In preclinical models, Tibric acid, given orally, was more effective than clofibrate in preventing the hyperlipemic and hypercholesteremic effects of various diets in rats. At high concentrations in vitro, Tibric acid moderately inhibited ADP- or thrombin-induced aggregation of rabbit blood platelets. In patients with severe type IV hyperlipoproteinemia and chylomicronemia, Tibric Acid lowered serum triglyceride and cholesterol values but administration of Tibric Acid to a normal subject did not affect serum lipid levels.